Enable Comprehensive Genomic Profiling

Assess all key biomarkers in guidelines, as well as clinical trials, increasing the chances of finding a positive biomarker for every sample. Including all key genomic variants, plus the immuno-oncology biomarkers MSI and TMB (emerging), our assays enable a lab to consolidate several independent assays and workflows into a single one, at the same time saving sample, time, and money.

---

Implement Assays In-house

Implement the assay in-house, to better serve your local community, maintain control of sample and data, and become an active part of the molecular tumor board. With content including current and emerging biomarkers, plus an IVD roadmap in partnership with several pharmaceutical companies, these assays are made to stay in a lab for the long run.

---

Integrated, Flexible, and Scalable Workflow

Assess all biomarkers in a single integrated 4-5 day workflow, including solutions to analyze data all the way to a complete final interpretation report. Provide flexibility to your customers, by enabling comprehensive genomic profiling from either solid or liquid biopsy samples, and scalable sample batch sizes, to meet any sample volume demand.

---

Achieve Reliable Results

Achieve reliable results with a family of assays with 99.999% analytical specificity and >95% analytical sensitivity, due to robust hybrid-capture chemistry, SBS sequencing, and sophisticated bioinformatics.